TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 184 filers reported holding TG THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.79 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,223,879 | -96.9% | 146,397 | -90.8% | 0.00% | -97.5% |
| Q2 2023 | $39,412,908 | +214.3% | 1,586,671 | +90.3% | 0.04% | +207.7% |
| Q1 2023 | $12,540,006 | -51.9% | 833,777 | -62.2% | 0.01% | -55.2% |
| Q4 2022 | $26,076,041 | +528.3% | 2,204,230 | +214.4% | 0.03% | +480.0% |
| Q3 2022 | $4,150,000 | -19.6% | 701,000 | -42.2% | 0.01% | -16.7% |
| Q2 2022 | $5,159,000 | +100.7% | 1,213,778 | +349.0% | 0.01% | +200.0% |
| Q1 2022 | $2,571,000 | +693.5% | 270,351 | +1487.1% | 0.00% | – |
| Q4 2021 | $324,000 | -49.9% | 17,034 | -12.4% | 0.00% | -100.0% |
| Q3 2021 | $647,000 | -89.4% | 19,438 | -87.7% | 0.00% | -80.0% |
| Q2 2021 | $6,113,000 | -76.3% | 157,580 | -70.5% | 0.01% | -80.0% |
| Q1 2021 | $25,787,000 | -42.9% | 535,001 | -38.4% | 0.02% | -37.5% |
| Q4 2020 | $45,178,000 | +222.4% | 868,479 | +65.9% | 0.04% | +185.7% |
| Q3 2020 | $14,011,000 | +132.0% | 523,587 | +68.9% | 0.01% | +100.0% |
| Q2 2020 | $6,040,000 | +117.7% | 310,043 | +10.0% | 0.01% | +75.0% |
| Q1 2020 | $2,774,000 | -71.8% | 281,893 | -68.2% | 0.00% | -63.6% |
| Q4 2019 | $9,836,000 | +881.6% | 886,088 | +396.2% | 0.01% | +1000.0% |
| Q3 2019 | $1,002,000 | +31.8% | 178,566 | +103.2% | 0.00% | 0.0% |
| Q2 2019 | $760,000 | -65.4% | 87,869 | -67.9% | 0.00% | -66.7% |
| Q1 2019 | $2,199,000 | +633.0% | 273,567 | +274.7% | 0.00% | – |
| Q4 2018 | $300,000 | +270.4% | 73,014 | +405.6% | 0.00% | – |
| Q3 2018 | $81,000 | -97.6% | 14,441 | -94.4% | 0.00% | -100.0% |
| Q2 2018 | $3,387,000 | +9.7% | 257,574 | +18.5% | 0.00% | 0.0% |
| Q1 2018 | $3,087,000 | +326.4% | 217,424 | +146.3% | 0.00% | +300.0% |
| Q4 2017 | $724,000 | -56.1% | 88,271 | -36.7% | 0.00% | -66.7% |
| Q3 2017 | $1,651,000 | +168.0% | 139,356 | +127.2% | 0.00% | +200.0% |
| Q2 2017 | $616,000 | +15.6% | 61,337 | +34.2% | 0.00% | 0.0% |
| Q1 2017 | $533,000 | -60.5% | 45,713 | -43.8% | 0.00% | -50.0% |
| Q2 2015 | $1,349,000 | +42.0% | 81,342 | +32.6% | 0.00% | +100.0% |
| Q1 2015 | $950,000 | – | 61,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| M28 Capital Management LP | 726,200 | $3,086,000 | 3.46% |
| Paradigm Biocapital Advisors LP | 1,964,709 | $8,350,000 | 1.66% |
| 683 Capital Management, LLC | 3,300,000 | $14,025,000 | 0.99% |
| MAVERICK CAPITAL LTD | 6,747,549 | $28,677,000 | 0.71% |
| Antara Capital LP | 1,500,000 | $6,375,000 | 0.27% |
| Parkwood LLC | 47,168 | $1,375,000 | 0.24% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,677,500 | $11,379,000 | 0.24% |
| PURA VIDA INVESTMENTS, LLC | 950,813 | $4,041,000 | 0.24% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 567,576 | $2,412,000 | 0.20% |
| Antara Capital LP | 900,000 | $3,825,000 | 0.16% |